 |
12 Diseases |  |
17 Trials |
|
17 Trials |  |
2487 News |  |
| «12...13141516171819202122232425 |
- ||||| Aimovig (erenumab-aooe) / Amgen, Novartis
New P2 trial: A Safety and Efficacy Study to Evaluate AMG 334 in Migraine Prevention (clinicaltrials.gov) - Dec 15, 2015
P2, N=459, Recruiting, Sponsor: Amgen
- |||| Aimovig (erenumab-aooe) / Amgen, Novartis
Enrollment open: Treadmill Cardiovascular Safety Study of Erenumab (AMG 334) (clinicaltrials.gov) - Dec 3, 2015
P2, N=120, Recruiting, Sponsor: Amgen
Not yet recruiting --> Recruiting
- Aimovig (erenumab-aooe) / Amgen, Novartis
Enrollment open: To Evaluate the Blockade of CGRP in Preventing PACAP-38 Induced Migraine-like Attacks With AMG 334 in Migraine Patients (clinicaltrials.gov) - Nov 21, 2015
P1, N=42, Recruiting, Sponsor: Amgen
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- || Aimovig (erenumab-aooe) / Amgen, Novartis
Trial primary completion date: A Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Chronic Migraine Prevention (clinicaltrials.gov) - Nov 11, 2015
P2, N=651, Recruiting, Sponsor: Amgen
Not yet recruiting --> Recruiting Trial primary completion date: Jul 2016 --> Feb 2016
- ||||| Aimovig (erenumab-aooe) / Amgen, Novartis
New P2 trial: Treadmill Cardiovascular Safety Study of Erenumab (AMG 334) (clinicaltrials.gov) - Oct 22, 2015
P2, N=120, Not yet recruiting, Sponsor: Amgen
- || Aimovig (erenumab-aooe) / Amgen, Novartis
Trial primary completion date: A Study to Assess the Long-term Safety and Efficacy of Erenumab (AMG 334) in Chronic Migraine Prevention. (clinicaltrials.gov) - Oct 2, 2015
P2, N=490, Recruiting, Sponsor: Amgen
Trial primary completion date: Jul 2016 --> Feb 2016 Trial primary completion date: Sep 2016 --> Apr 2017
- | Aimovig (erenumab-aooe) / Amgen, Novartis
New P1 trial: To Evaluate the Blockade of CGRP in Preventing PACAP-38 Induced Migraine-like Attacks With AMG 334 in Migraine Patients (clinicaltrials.gov) - Sep 8, 2015
P1, N=42, Not yet recruiting, Sponsor: Amgen
- ||| Aimovig (erenumab-aooe) / Amgen, Novartis
Enrollment change, Trial primary completion date: A Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Chronic Migraine Prevention (clinicaltrials.gov) - Aug 25, 2015
P2, N=651, Recruiting, Sponsor: Amgen
Trial primary completion date: Sep 2016 --> Apr 2017 N=490 --> 651 | Trial primary completion date: Feb 2016 --> Jul 2016
- |||||| Aimovig (erenumab-aooe) / Amgen, Novartis
Enrollment open: ARISE: Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) Compared to Placebo in Migraine Prevention (clinicaltrials.gov) - Aug 13, 2015
P3, N=540, Recruiting, Sponsor: Amgen
N=490 --> 651 | Trial primary completion date: Feb 2016 --> Jul 2016 Not yet recruiting --> Recruiting
- |||||| Aimovig (erenumab-aooe) / Amgen, Novartis
Enrollment open: STRIVE: Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention (clinicaltrials.gov) - Aug 13, 2015
P3, N=852, Recruiting, Sponsor: Amgen
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||||||||| Aimovig (erenumab-aooe) / Amgen, Novartis
New P3 trial: ARISE: Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) Compared to Placebo in Migraine Prevention (clinicaltrials.gov) - Jun 29, 2015
P3, N=540, Not yet recruiting, Sponsor: Amgen
- |||||||||| Aimovig (erenumab-aooe) / Amgen, Novartis
New P3 trial: STRIVE: Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention (clinicaltrials.gov) - May 28, 2015
P3, N=852, Not yet recruiting, Sponsor: Amgen
- ||| Aimovig (erenumab-aooe) / Amgen, Novartis
Trial completion: Study of Erenumab (AMG 334) in Women With Hot Flashes (clinicaltrials.gov) - Nov 13, 2014
P1, N=103, Completed, Sponsor: Amgen
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- || Aimovig (erenumab-aooe) / Amgen, Novartis
Trial primary completion date: Study of Erenumab (AMG 334) in Women With Hot Flashes (clinicaltrials.gov) - Oct 4, 2014
P1, N=103, Active, not recruiting, Sponsor: Amgen
Active, not recruiting --> Completed Trial primary completion date: Mar 2014 --> Aug 2014
- | Aimovig (erenumab-aooe) / Amgen, Novartis
Trial completion: Ascending Multiple-Doses of Erenumab (AMG 334) in Healthy Adults and in Migraine Patients (clinicaltrials.gov) - Jul 30, 2014
P1, N=48, Completed, Sponsor: Amgen
Trial primary completion date: Mar 2014 --> Aug 2014 Active, not recruiting --> Completed
- ||| Aimovig (erenumab-aooe) / Amgen, Novartis
Enrollment closed: OLTP: Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention (clinicaltrials.gov) - Jul 15, 2014
P2, N=483, Active, not recruiting, Sponsor: Amgen
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||| Aimovig (erenumab-aooe) / Amgen, Novartis
Enrollment open: A Study to Assess the Long-term Safety and Efficacy of Erenumab (AMG 334) in Chronic Migraine Prevention. (clinicaltrials.gov) - Jul 10, 2014
P2, N=490, Recruiting, Sponsor: Amgen
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||||| Aimovig (erenumab-aooe) / Amgen, Novartis
New P2 trial: A Study to Assess the Long-term Safety and Efficacy of Erenumab (AMG 334) in Chronic Migraine Prevention. (clinicaltrials.gov) - Jun 27, 2014
P2, N=490, Not yet recruiting, Sponsor: Amgen
- |||| Aimovig (erenumab-aooe) / Amgen, Novartis
Enrollment open: A Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Chronic Migraine Prevention (clinicaltrials.gov) - Jun 3, 2014
P2, N=490, Recruiting, Sponsor: Amgen
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Aimovig (erenumab-aooe) / Amgen, Novartis
Trial completion date: Study of Erenumab (AMG 334) in Women With Hot Flashes (clinicaltrials.gov) - May 14, 2014
P1, N=103, Active, not recruiting, Sponsor: Amgen
Not yet recruiting --> Recruiting Trial completion date: Apr 2014 --> Aug 2014
- ||||| Aimovig (erenumab-aooe) / Amgen, Novartis
New P2 trial: A Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Chronic Migraine Prevention (clinicaltrials.gov) - Feb 17, 2014
P2, N=490, Not yet recruiting, Sponsor: Amgen
- || Aimovig (erenumab-aooe) / Amgen, Novartis
Enrollment closed: Study of Erenumab (AMG 334) in Women With Hot Flashes (clinicaltrials.gov) - Jan 21, 2014
P1, N=103, Active, not recruiting, Sponsor: Amgen
Trial completion date: Apr 2014 --> Aug 2014 Recruiting --> Active, not recruiting
- Aimovig (erenumab-aooe) / Amgen, Novartis
Enrollment change: Ascending Multiple-Doses of Erenumab (AMG 334) in Healthy Adults and in Migraine Patients (clinicaltrials.gov) - Jan 13, 2014
P1, N=48, Active, not recruiting, Sponsor: Amgen
Recruiting --> Active, not recruiting N=40 --> 48
- Aimovig (erenumab-aooe) / Amgen, Novartis
Enrollment closed: Ascending Multiple-Doses of Erenumab (AMG 334) in Healthy Adults and in Migraine Patients (clinicaltrials.gov) - Jan 13, 2014
P1, N=48, Active, not recruiting, Sponsor: Amgen
N=40 --> 48 Recruiting --> Active, not recruiting
- ||| Aimovig (erenumab-aooe) / Amgen, Novartis
Trial completion: Ascending Single Doses of Erenumab (AMG 334) in Healthy Adults and Migraine Patients (clinicaltrials.gov) - Jan 7, 2014
P1, N=60, Completed, Sponsor: Amgen
Recruiting --> Active, not recruiting Terminated --> Completed
- ||||| Aimovig (erenumab-aooe) / Amgen, Novartis
New P2 trial: OLTP: Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention (clinicaltrials.gov) - Sep 26, 2013
P2, N=468, Recruiting, Sponsor: Amgen
- ||| Aimovig (erenumab-aooe) / Amgen, Novartis
New P1 trial: Study of Erenumab (AMG 334) in Women With Hot Flashes (clinicaltrials.gov) - Jun 27, 2013
P1, N=103, Active, not recruiting, Sponsor: Amgen
- | Aimovig (erenumab-aooe) / Amgen, Novartis
New P1 trial: Ascending Multiple-Doses of Erenumab (AMG 334) in Healthy Adults and in Migraine Patients (clinicaltrials.gov) - Nov 6, 2012
P1, N=48, Active, not recruiting, Sponsor: Amgen
- ||| Aimovig (erenumab-aooe) / Amgen, Novartis
New P1 trial: Ascending Single Doses of Erenumab (AMG 334) in Healthy Adults and Migraine Patients (clinicaltrials.gov) - Sep 18, 2012
P1, N=60, Completed, Sponsor: Amgen